Vendor Intelligence Report: Qingdao Meipeptide Technology

Executive summary

Across 4 Finnrick lab tests, Qingdao Meipeptide Technology is 2 pass / 2 fail, for an overall pass rate of 50%. The testing signal is narrow rather than catalog-wide: retatrutide is the only product in the dossier with independent coverage. That makes Meipeptide a more evidence-backed retatrutide option than an untested storefront, but the split record and methodology-sensitive grading make batch-specific verification the central buyer decision.

The business record is much thinner than the sales pitch. GlobalSources materials claim a long operating history and in-house R&D/production, but the public-source run did not locate formation filings, named owners, named executives, facility licenses, or sufficient web history to verify that claim. Registry access barriers and repeated website timeouts leave buyers with a vendor identity, platform ID, domains, and sales aliases, but not a clear accountable corporate trail.

The operational network is the sharper risk. Forum order reports tie Qingdao Meipeptide to Huaian Hanyou through the same sales contact, Selena, while Huaian Hanyou carries separate delivery/scam allegations and a weaker quality profile in Finnrick's broader ecosystem. At the same time, meipeptide.com and related endpoints timed out during the field run, Scamadviser assigned meipeptide.com a 1/100 trust score, Gridinsoft classified it as fraudulent e-commerce, and Bitcoin acceptance raises dispute-recovery risk.

Customer reports are not uniformly negative: some buyers describe tracking, month-long delivery, responsive communication, professional packaging, and vendor-supplied Janoshik reports. The report treats those as fulfillment signals, not proof of chemical quality, especially where COA vendor names may not match and non-retatrutide products have no Finnrick-supported record.

Inside the full report:

• Appendix A laboratory data, methodology-divergence charts, and rating trajectory for the tested retatrutide line
• Corporate identity and absence-trail review across GlobalSources, Tianyancha, OpenCorporates, ICANN, Wayback, Alibaba, and Trustpilot
• Sister-brand network analysis covering Qingdao Meipeptide, Huaian Hanyou, Guangzhou Meipeptide, Selena, and MEI-PEPTIDE/BeautyPeptide variants
• Website authenticity and security review for meipeptide.com, the GlobalSources storefront, Huaian Hanyou domains, Scamadviser, and Gridinsoft
• Buyer-report analysis covering delivery anecdotes, Janoshik COA verification issues, packaging reports, and Huaian Hanyou dispute allegations

Risk assessment

• Retatrutide testing reliability concern — high: Retatrutide is the only Finnrick-tested product and shows 4 tests (2 pass / 2 fail) with a 73.88% current rating; buyers should batch-verify before use.
• Untested non-retatrutide catalog concern — medium: All catalog items other than retatrutide have no Finnrick testing record in the supplied data; retatrutide results should not be treated as catalog-wide evidence.
• Corporate-identity opacity and unverified history claim — high: No named owners/executives or formation records were identified in public OSINT; the claimed 20 years of experience remains unverified.
• Website security and authenticity-verification risk — high: meipeptide.com and the GlobalSources storefront timed out; Scamadviser rates meipeptide.com 1/100 and Gridinsoft flags it as fraudulent, with no clear authorized-channel or anti-counterfeit scheme found.
• Sister-brand operational-contagion risk — medium: Qingdao Meipeptide is linked by reports to Huaian Hanyou and Guangzhou Meipeptide, including shared sales contact Selena; Huaian Hanyou has recent non-delivery/scam allegations.
• Irreversible-payment risk — medium: Scamadviser reports Bitcoin acceptance, increasing buyer exposure if an order is delayed, misrouted, or disputed.